| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 2002;123:1114-1119
© 2002 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology (CSP) |
From the Division of Cardiac Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada,a and the Division of Cardiac Surgery, Foothills Hospital, University of Calgary, Calgary, Alberta, Canada.b
Supported by the Heart and Stroke Foundation of Ontario (R.D.W.), Canadian Diabetes Association (R.D.W., V.R., S.V.), and Physicians Services Incorporated (S.V., R.D.W.). S.V. and P.W.M.F. are fellows of the Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada. S.V. was the C. Walton Lillehei Forum Finalist.
Read at the Eighty-first Annual Meeting of The American Association for Thoracic Surgery, San Diego, Calif, May 6-9, 2001.
Received for publication May 15, 2001. Revisions requested July 9, 2001; revisions received Nov 12, 2001. Accepted for publication Nov 13, 2001. Address for reprints: Richard D. Weisel, MD, FRCSC, Professor and Chairman, Division of Cardiac Surgery, The Toronto General Hospital, EN 14-215, 200 Elizabeth St, Toronto, Ontario, M5G 2C4 Canada (E-mail: richard.weisel{at}uhn.on.ca).
Objectives: Evidence has accrued to suggest that diabetic patients face an increased risk of ischemic events and low output syndrome and might mount an inordinate response to ischemia and reperfusion. Because hyperglycemia is a potent stimulus for endothelin-1 production, we hypothesized that increased production, action, or both of endothelin-1 in diabetes might represent an important mediator of endothelial dysfunction in patients with that disease. To this aim, we compared the effects of cardioplegic arrest and reperfusion on coronary sinus effluent endothelin-1 levels and atrial arteriolar vascular responses in diabetic and case-matched nondiabetic patients undergoing coronary artery bypass grafting.
Methods: In study 1 coronary sinus effluent endothelin-1 levels were assessed at baseline and at 1 and 10 minutes after reperfusion in 13 diabetic and 12 nondiabetic patients matched for age, ejection fraction, Parsonnet score, and crossclamp time. In study 2 vascular responses of atrial arterioles subjected to perioperative ischemia-reperfusion were evaluated with videomicroscopy. Atrial microvessels (from appendages) were obtained before and after removal of the aortic crossclamp, and vascular responses to exogenously administered endothelin-1 (10-10 mol/L) and substance P (10-8 mol/L) were studied in the presence or absence of BQ-123, an endothelin A receptor antagonist.
Results: Diabetic patients elaborated more endothelin-1 at 1 and 10 minutes after reperfusion (P = .01). Endothelin-1-mediated vasoconstriction was similar in diabetic and nondiabetic atrial microvessels before cardioplegic arrest and cardiopulmonary bypass. After cardiopulmonary bypass and reperfusion, endothelin-1-mediated vasoconstriction was enhanced in both groups; however, this response was greater in microvessels from diabetic patients (P = .02). BQ-123, the endothelin A antagonist, attenuated the effects of bypass and reperfusion on endothelin-1-mediated vasoconstriction in both groups (P = .01). Substance P-mediated vasodilatation was similar in diabetic and nondiabetic atrial microvessels before bypass. After bypass and reperfusion, substance P-mediated vasodilatation was diminished in both groups; however, this response was more pronounced in the diabetic group (P = .003). BQ-123 coincubation restored substance P-mediated vasodilatation in both groups.
Conclusions: We determined the following: (1) the coronary effluent release of endothelin-1 is higher in diabetic than in nondiabetic patients after cardiopulmonary bypass and reperfusion; (2) diabetic coronary microvessels respond to bypass and reperfusion with greater endothelin-1-mediated vasoconstriction and diminished nitric oxide-mediated vasodilatation; and (3) these effects are attenuated by endothelin antagonism. Endothelin-1 might be an important mediator of ischemia-reperfusion injury in patients with diabetes. Furthermore, use of endothelin receptor antagonists might be a novel strategy for improving the resistance of the diabetic heart to cardioplegic arrest and reperfusion.
Related Article
J. Thorac. Cardiovasc. Surg. 2002 123: 1031-1034.
This article has been cited by other articles:
|
|
 |
|
  I. Lekli, G. Szabo, B. Juhasz, S. Das, M. Das, E. Varga, L. Szendrei, R. Gesztelyi, J. Varadi, I. Bak, et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H859 - H866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Deschamps, J. Zavadzkas, R. L. Murphy, C. N. Koval, J. E. McLean, L. Jeffords, S. M. Saunders, N. J. Sheats, R. E. Stroud, and F. G. Spinale Interruption of endothelin signaling modifies membrane type 1 matrix metalloproteinase activity during ischemia and reperfusion Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H875 - H883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bohm and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res, October 1, 2007; 76(1): 8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Apple, J. E. McLean, C. E. Squires, B. Schaeffer, J. A. Sample, R. L. Murphy, A. M. Deschamps, A. H. Leonardi, C. M. Allen, J. W. Hendrick, et al. Differential Effects of Protein Kinase C Isoform Activation in Endothelin-Mediated Myocyte Contractile Dysfunction With Cardioplegic Arrest and Reperfusion Ann. Thorac. Surg., August 1, 2006; 82(2): 664 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Deschamps and F. G. Spinale Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation Cardiovasc Res, February 15, 2006; 69(3): 666 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Xia, K.-H. Kuo, D. V. Godin, M. J. Walker, M. C. Y. Tao, and D. M. Ansley 15-F2t-isoprostane exacerbates myocardial ischemia-reperfusion injury of isolated rat hearts Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1366 - H1372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Multani, J. S. Ikonomidis, P. Y. Kim, E. A. Miller, K. J. Payne, R. Mukherjee, B. H. Dorman, and F. G. Spinale Dynamic and differential changes in myocardial and plasma endothelin in patients undergoing cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., March 1, 2005; 129(3): 584 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Voisine, M. Ruel, T. A. Khan, C. Bianchi, S.-H. Xu, I. Kohane, T. A. Libermann, H. Otu, A. R. Saltiel, and F. W. Sellke Differences in Gene Expression Profiles of Diabetic and Nondiabetic Patients Undergoing Cardiopulmonary Bypass and Cardioplegic Arrest Circulation, September 14, 2004; 110(11_suppl_1): II-280 - II-286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Verma, A. W. Miller, and D. W. Busija Endothelin Antagonism and Insulin's Vascular Effects * Response: Endothelin Antagonism and Insulin's Vascular Effects Hypertension, December 1, 2002; 40 (6): e12 - e13. [Full Text] [PDF]
|
|
|
|
|
|
F. G. Spinale The bioactive peptide endothelin causes multiple biologic responses relevant to myocardial and vascular performance after cardiac surgery J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1031 - 1034. [Full Text] [PDF]
|
|
|
|
|
|
S. Verma, A. Maitland, R. D. Weisel, S.-H. Li, P. W. M. Fedak, N. C. Pomroy, D. A. G. Mickle, R.-K. Li, L. Ko, and V. Rao Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: Reversal with endothelin antagonism J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1120 - 1124. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
